Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose /multiple ascending dose study evaluating NMRA-266 in healthy adult participants. NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. Neumora believes that as a selective M4 receptor-positive allosteric modulator, NMRA-266 has the potential to deliver antipsychotic efficacy, while minimizing the side effects associated with current antipsychotics and other non-selective muscarinic agonists.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.675 USD | +0.26% | +0.82% | -43.06% |
05-14 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
05-14 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.06% | 1.54B | |
+65.25% | 62.59B | |
-1.27% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.34% | 26.21B | |
-21.77% | 19.09B | |
+4.92% | 13.08B | |
+25.53% | 12.26B | |
+28.61% | 12.05B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study